natgillin/translations-raw huggingface dataset:
Other information about Prac-tic: 
Druge informacije o zdravilu Prac-tic:
Two field studies were conducted in dogs at veterinary practices in several European countries and different geographic regions. 
Dve terenski preskušanji sta bili izvedeni pri psih v veterinarskih ambulantah v nekaterih evropskih državah in v različnih geografskih regijah.
Prac-tic should not be used in dogs less than 8 weeks old or less than 2 kg bodyweight since it has not sufficiently been studied in these animals. 
Zdravilo Prac-tic se ne sme uporabljati pri psih, ki so stari manj kot 8 tednov ali imajo manj kot 2 kg telesne mase, saj pri teh skupinah živali zdravilo ni bilo zadostno raziskano.
This product is specifically developed for dogs and should not be used in any other animal species. 
To zdravilo je bilo razvito posebej za pse in se ne sme uporabljati pri drugih živalskih vrstah.
For large dogs a combination of pipettes might be needed to achieve the correct dose. 
Pri večjih psih bo morda treba uporabiti kombinacijo več merilnih kapalk, da se doseže ustrezni odmerek.
Data were provided on the pharmaceutical quality, the tolerance of the product in dogs and the safety in humans (people in contact with the product) and the environment. 
Predloženi so bili podatki o farmacevtski kakovosti, toleranci na zdravilo pri psih ter njegovi varnosti za ljudi (ljudi, ki pridejo v stik z zdravilom) in okolje.
The medicine killed fleas within 24 hours and ticks within 48 hours after treatment and its effectiveness lasted for at least 4 weeks. 
Zdravilo uniči bolhe v 24 urah, klope pa v 48 urah po uporabi zdravila, njegov učinek pa traja najmanj 4 tedne.
Pyriprole, interacts with a receptor involved in transmitting neural impulses (GABA receptor). 
Piriprol vzajemno deluje z receptorjem, ki igra vlogo pri prenosu živčnih dražljajev (receptorjem GABA).
This interferes with the nervous system of fleas or ticks and leads to the death of these parasites. 
To zaviralno deluje na živčni sistem bolh ali klopov ter povzroči smrt teh zajedavcev.
What benefit has Prac-tic shown during the studies? 
Kakšne koristi je zdravilo Prac-tic izkazalo med študijami?
The effectiveness was measured looking at the number of live ticks or number of fleas at various times up to 3 months after application. 
Učinkovitost so merili z ugotavljanjem števila živih klopov ali števila bolh ob različnih časovnih obdobjih, in sicer do 3 mesecev po uporabi zdravila.
Pyripole 
Prac-tic piriprol
As a precautionary measure, direct contact with the treated dog should be avoided and children should not be allowed to play with a treated animal until the application site is dry. 
Iz preventivnih razlogov se je treba izogibati neposrednemu stiku z zdravljenim psom in preprečiti otrokom igranje z zdravljeno živaljo, dokler področje nanosa ni suho.
What is the risk associated with Prac-tic? 
Kakšna tveganja so povezana z zdravilom Prac-tic?
As other products of this group, Prac-tic should not be used in sick animals or dogs that have just recovered from illness. 
Kot to velja za ostala zdravila iz te skupine zdravil, se zdravilo Prac-tic ne sme uporabljati pri bolnih živalih ali psih, ki so pravkar okrevali po bolezni.
Prac-tic should not be allowed to enter surface water, as it may be harmful for aquatic organisms. 
Zdravilo Prac-tic ne sme zaiti v vodotoke, ker je lahko nevarno za vodne organizme.
Skin contact with the pipette content should be avoided. 
Stiku vsebine merilne kapalke s kožo se je treba izogibati.
The effectiveness of pyriprole against flea and tick infestations in dogs was investigated in laboratory studies and in field trials. 
Učinkovitost piriprola zoper infestacije z bolhami in klopi pri psih je bila raziskana v laboratorijskih raziskavah in terenskih preskušanjih.
Dogs from various breeds, age groups and weight that were infested with fleas or ticks were either treated with Prac-tic or with other products authorised in the EU for this indication. 
Pse različnih ras, starostnih skupin in z različnimi telesnimi masami, ki so bili infestirani z bolhami in klopi, so zdravili bodisi z zdravilom Prac-tic bodisi z drugimi zdravili, ki so bila v EU odobrena za to indikacijo.
It is given to dogs with pre-filled spot-on pipettes, i.e. small plastic containers which are already filled with the correct amount of Prac-tic needed to treat one dog (Pract-tic is available in 4 different sizes for different dog sizes). 
majhnimi plastičnimi cevkami, ki so že napolnjene z ustrezno količino zdravila Prac-tic, potrebno za zdravljenje enega psa (zdravilo Prac-tic je na voljo v 4 različnih velikostih, ki ustrezajo različnim velikostim psov).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Prac-tic exceed the risks for the approved indications and recommended that Prac-tic be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Prac-tic večje od z njim povezanih tveganj, kadar se zdravilo uporablja za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
The most common side effects in dogs are local reactions at the place where the product has been applied: change in the fur colour, hair loss and itchiness, as well as change in appearance of the fur (greasy appearance and clumpiness). 
Najpogostejši neželeni učinki pri psih so lokalne reakcije na mestu nanosa zdravila: sprememba barve dlak, izpadanje dlak in srbečica ter sprememba videza dlak (masten videz in sprijete dlake).
If a dog licks the application area, the dog might salivate a lot for a short period. 
Če pes liže mesto nanosa, se lahko pri njem pojavi kratko obdobje prekomernega slinjenja.
Why has Prac-tic been approved? 
Zakaj je bilo zdravilo Prac-tic odobreno?
The results of the field trials showed that Prac-tic is effective in the treatment and prevention of flea and tick infestations in dogs. 
Rezultati terenskih preskušanj so pokazali, da je zdravilo Prac-tic učinkovito pri zdravljenju in preprečevanju infestacij z bolhami in klopi pri psih.
Prac-tic is an “ectoparasiticide”, which means that it will kill parasites that live on the skin or in the fur of animals, such as fleas and ticks. 
Prac-tic je zdravilo za zatiranje zunanjih zajedavcev, kar pomeni, da uničuje zajedavce, ki živijo na koži ali v dlaki živali, kot so denimo bolhe in klopi.
Prac-tic is used to treat and to prevent tick and flea infestations in dogs. 
Zdravilo Prac-tic se uporablja za zdravljenje in preprečevanje infestacij s klopi in bolhami pri psih.
The content of the pipette is squeezed onto the skin after parting the fur in one up to three spots between the shoulder blades and down the backline of the dog. 
Psu razmaknemo dlako na enem do treh mestih med lopaticama in vzdolž njegove hrbtenice tako, da se prikaže koža, in na ta mesta stisnemo vsebino merilne kapalke.
What is Prac-tic used for? 
Za kaj se zdravilo Prac-tic uporablja?
How has Prac-tic been studied? 
Kako je bilo zdravilo Prac-tic raziskano?
Once applied, it remains active for at least 4 weeks. 
Učinek zdravila traja najmanj 4 tedne po njegovi uporabi.
People with known hypersensitivity to the phenylpyrazole class compounds or any of the excipients should avoid contact with Prac-tic. 
Stiku z zdravilom Prac-tic se morajo izogibati tudi ljudje, ki so preobčutljivi na snovi iz skupine fenilpirazolov ali na katere koli druge pomožne snovi zdravila.
Adult fleas are killed before they lay eggs; since Prac-tic completely eliminates egg production, it breaks the flea life cycle. 
S tem ko zdravilo Prac-tic povsem ustavi proizvodnjo jajčec, se življenjski cikel bolh prekine.
Skin should be washed and eyes should be rinsed with water, if accidental exposure occurred. 
V primeru nenamernega stika je treba kožo in oči sprati z vodo.
How does Prac-tic work? 
Kako zdravilo Prac-tic deluje?
Prac-tic is a spot-on solution that contains pyriprole as active substance. 
Zdravilo Prac-tic je na voljo v obliki raztopine za kožne kapljice, ki vsebuje zdravilno učinkovino piriprol.
What is Prac-tic? 
Kaj je zdravilo Prac-tic?
When administering Prac-tic, the user should not smoke, eat or drink. 
Ne kadite, jejte ali pijte, medtem ko rokujete z zdravilom Prac-tic.
50 x 1 tablet(unit dose) 105 tablets 
50 x 1 tableta (enoodmerni pretisni omot)
EMA Number 
Številka postopka EMA Ime
Desloratadine Teva Desloratadine Teva 
Pot uporabe Ovojnina
This finding was based on the results from 769 patients. 
Te ugotovitve so temeljile na izidih študije pri 769 bolnikih.
To manage side effects, treatment may have to be temporarily interrupted or the dose may be reduced. 
Za obvladovanje neželenih učinkov bo morda treba zdravljenje začasno prekiniti ali zmanjšati odmerek.
The European Commission granted a marketing authorisation valid throughout the European Union for Nexavar on 19 July 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Nexavar, veljavno po vsej Evropski uniji, izdala 19. julija 2006.
EPAR summary for the public sorafenib 
Povzetek EPAR za javnost sorafenib
Nexavar is given as two tablets twice a day, without food or with a meal that is low in fat. 
Zdravilo Nexavar se daje v dveh tabletah dvakrat na dan bodisi brez hrane ali z obrokom, ki vsebuje malo maščobe.
Because the numbers of patients with these diseases are low, the diseases are considered ‘rare', and Nexavar was designated an ‘orphan medicine' (a medicine used in rare diseases). 
Ker je bolnikov s temi boleznimi malo, veljajo bolezni za redke, zato je bilo zdravilo Nexavar določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja pri redkih boleznih).
Other information about Nexavar 
Druge informacije o zdravilu Nexavar
This is a summary of the European public assessment report (EPAR) for Nexavar. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nexavar.
For more information about treatment with Nexavar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Nexavar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The summaries of the opinions of the Committee for Orphan Medicinal Products for Nexavar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations: 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Nexavar je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
The CHMP decided that Nexavar's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Nexavar večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Nexavar is used to treat patients who have the following diseases: 
Zdravilo Nexavar se uporablja za zdravljenje bolnikov z naslednjimi boleznimi:
This finding was based on the results from all 903 patients, including about 200 who had switched from placebo to Nexavar before the end of the study. 
Ta ugotovitev je temeljila na izidih študije pri vseh 903 bolnikih, vključno z 200 bolniki, ki so pred koncem študije s placeba prešli na zdravilo Nexavar.
• hepatocellular carcinoma (11 April 2006) 
• hepatocelularni karcinom (11. april 2006)
Treatment with Nexavar should be supervised by doctors who have experience of anticancer treatments. 
Zdravljenje z zdravilom Nexavar mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
Nexavar has been compared with placebo (a dummy treatment) in three main studies. 
Zdravilo Nexavar so primerjali s placebom (zdravilom brez zdravilne učinkovine) v treh glavnih študijah.
The first study involved 602 patients with hepatocellular carcinoma; the second involved 903 patients with advanced renal cell carcinoma in whom one previous anticancer treatment had stopped working; and the third study involved 417 patients with differentiated thyroid carcinoma that had progressed or spread locally or to other parts of the body and did not respond to treatment with radioactive iodine. 
V prvi študiji sta sodelovala 602 bolnika s hepatocelularnim karcinomom, v drugi študiji 903 bolniki z napredovalim rakom ledvičnih celic, pri katerih predhodno zdravljenje proti raku ni bilo več učinkovito, tretja študija pa je zajela 417 bolnikov z diferenciranim karcinomom ščitnice, ki je bodisi napredoval, se razširil lokalno ali zajel tudi druge dele telesa in se ni odzval na zdravljenje z radioaktivnim jodom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nexavar. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
For the full list of all side effects and restrictions with Nexavar, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Nexavar glejte navodilo za uporabo.
• renal cell carcinoma (29 July 2004) 
• rak ledvičnih celic (29. julij 2004)
What benefit has Nexavar shown during the studies? 
Kakšne koristi je zdravilo Nexavar izkazalo med študijami?
• hepatocellular carcinoma (a type of liver cancer); 
• hepatocelularnim karcinomom (vrsto jetrnega raka);
These enzymes can be found in some receptors on the surface of cancer cells, where they are involved in the growth and spread of cancer cells, and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. 
Ti encimi so prisotni v nekaterih receptorjih na površini rakavih celic, kjer sodelujejo pri njihovi rasti in širjenju, ter v krvnih žilah, ki oskrbujejo tumorje, kjer sodelujejo pri nastanku novih krvnih žil.
• advanced renal cell carcinoma (a type of kidney cancer) when anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used; 
• napredovalim rakom ledvičnih celic (vrsto ledvičnega raka), če je bilo zdravljenje raka z interferonom alfa ali interlevkinom 2 neuspešno ali se ne more uporabiti;
The most common side effects with Nexavar are diarrhoea, rash, alopecia (hair loss), infection, hand foot skin reaction (rash and pain on the palms of the hands and soles of the feet) and fatigue (tiredness). 
Najpogostejši neželeni učinki zdravila Nexavar so driska, izpuščaji, alopecija (izpadanje las), okužbe, reakcije na koži dlani in stopal (izpuščaji in bolečine na dlaneh in stopalih) ter utrujenost.
The most important serious side effects are myocardial infarction (heart attack) or ischaemia (reduced oxygen supply to the heart), gastrointestinal perforation (a hole that develops in the wall of the gut), drug-induced hepatitis (a disease of the liver), haemorrhage (bleeding) and hypertension or hypertensive crisis (high blood pressure). 
Najpomembnejši resni neželeni učinki so miokardni infarkt (srčni napad) ali ishemija (zmanjšana oskrba srca s kisikom), gastrointestinalna perforacija (nastanek lukenj v črevesni steni), z zdravili povzročen hepatitis (obolenje jeter), krvavitve in hipertenzija (povišan krvni tlak) ali hipertenzivna kriza (nenadno povišanje krvnega tlaka).
The active substance in Nexavar, sorafenib, is a protein kinase inhibitor. 
Zdravilna učinkovina v zdravilu Nexavar, sorafenib, je zaviralec proteinske kinaze.
The treatment is continued as long as the patient continues to benefit from it without too many side effects. 
Zdravljenje traja tako dolgo, dokler še koristi bolniku oziroma dokler neželeni učinki zdravljenja niso prekomerni.
The main measures of effectiveness were how long the patients survived or how long the patients lived without their disease getting worse. 
Glavni merili učinkovitosti sta bili čas preživetja ali čas preživetja brez napredovanja bolezni.
Nexavar was more effective than placebo in increasing how long the patients survived or how long the patients lived without their disease getting worse. 
Zdravilo Nexavar je bilo učinkovitejše od placeba pri podaljševanju časa preživetja ali časa preživetja brez napredovanja bolezni.
The patients taking Nexavar lived for longer without their disease getting worse (167 days, around five and a half months) than those who took placebo (84 days, around three months). 
Pri bolnikih, ki so jemali zdravilo Nexavar, je bil čas preživetja brez napredovanja bolezni daljši (167 dni, približno pet mesecev in pol) kot pri bolnikih, ki so jemali placebo (84 dni, približno tri mesece).
What is the risk associated with Nexavar? 
Kakšna tveganja so povezana z zdravilom Nexavar?
By blocking these enzymes, Nexavar can reduce the growth of cancer cells and cut off the blood supply that keeps cancer cells growing. 
Zdravilo Nexavar lahko z blokiranjem teh encimov zavre rast in širjenje raka ter prekine dotok krvi do rakavih celic, ki omogoča njihovo rast.
• differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland) when the cancer has progressed or spread locally or to other parts of the body and does not respond to treatment with radioactive iodine. 
• diferenciranim karcinomom ščitnice (vrsto raka, ki izvira iz folikularnih celic žleze ščitnice), kadar je rak napredoval ali se začel širiti lokalno ali v druge dele telesa in se ne odziva na zdravljenje z radioaktivnim jodom.
Nexavar is a cancer medicine that contains the active substance sorafenib. 
Nexavar je zdravilo proti raku, ki vsebuje zdravilno učinkovino sorafenib.
Why has Nexavar been approved? 
Zakaj je bilo zdravilo Nexavar odobreno?
• papillary thyroid cancer and follicular thyroid cancer (13 November 2013) The full EPAR for Nexavar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nexavar je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In the study of hepatocellular carcinoma, the patients taking Nexavar survived for an average of 10.7 months, compared with 7.9 months in those taking placebo. 
V študiji hepatocelularnega karcinoma so bolniki, ki so jemali zdravilo Nexavar, preživeli v povprečju 10,7 meseca, bolniki, ki so jemali placebo, pa 7,9 meseca.
In the study of renal cell carcinoma, the patients taking Nexavar survived for an average of 19.3 months, compared with 15.9 months in those taking placebo. 
V študiji raka ledvičnih celic so bolniki, ki so jemali zdravilo Nexavar, preživeli v povprečju 19,3 meseca, bolniki, ki so jemali placebo, pa 15,9 meseca.
What is Nexavar used for? 
Za kaj se zdravilo Nexavar uporablja?
In the study in differentiated thyroid carcinoma, the patients taking Nexavar lived for an average of 10.8 months without their disease getting worse, compared with 5.8 months in those taking placebo. 
V študiji diferenciranega karcinoma ščitnice je bil pri bolnikih, ki so jemali zdravilo Nexavar, čas preživetja brez napredovanja bolezni v povprečju 10,8 meseca, pri bolnikih, ki so jemali placebo, pa 5,8 meseca.
What is Nexavar? 
Kaj je zdravilo Nexavar?
How has Nexavar been studied? 
Kako je bilo zdravilo Nexavar raziskano?
How does Nexavar work? 
Kako zdravilo Nexavar deluje?
How is Nexavar used? 
Kako se zdravilo Nexavar uporablja?
It is available as tablets (250 mg, 500 mg, 750 mg and 1,000 mg). 
Na voljo je v obliki tablet (250, 500, 750 in 1 000 mg).
The full EPAR for Levetiracetam Actavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Levetiracetam Actavis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Actavis on 3 October 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Levetiracetam Actavis, veljavno po vsej Evropski uniji, odobrila dne 3. oktobra 2011.
For more information about treatment with Levetiracetam Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Levetiracetam Actavis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This helps Levetiracetam Actavis to stabilise electrical activity in the brain and prevent seizures. 
To omogoča zdravilu Levetiracetam Actavis, da stabilizira električno aktivnost v možganih in prepreči napade.
This means that Levetiracetam Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra. 
To pomeni, da je „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Keppra.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Actavis. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Levetiracetam Actavis, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Levetiracetam Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Levetiracetam Actavis generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
This is a summary of the European public assessment report (EPAR) for Levetiracetam Actavis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levetiracetam Actavis.
What are the benefits and risks of Levetiracetam Actavis? 
Kakšne so koristi in tveganja, povezani z zdravilom Levetiracetam Actavis?
Other information about Levetiracetam Actavis 
Druge informacije o zdravilu Levetiracetam Actavis
Levetiracetam Actavis can also be used as an add-on to other anti-epileptic medicines to treat: 
Zdravilo Levetiracetam Actavis se lahko uporablja kot dopolnilno zdravljenje k drugim zdravilom proti epilepsiji za zdravljenje:
The Committee recommended that Levetiracetam Actavis be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Levetiracetam Actavis odobri dovoljenje za promet.
Because Levetiracetam Actavis is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra. 
Ker je zdravilo Levetiracetam Actavis generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Keppra.
Levetiracetam Actavis can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. 
Zdravilo Levetiracetam Actavis se lahko uporablja kot samostojno zdravilo pri bolnikih, starejših od 16 let, pri katerih so na novo odkrili epilepsijo, za zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje.
The CHMP concluded that, in accordance with EU requirements, Levetiracetam Actavis has been shown to have comparable quality and to be bioequivalent to Keppra. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Levetiracetam Actavis primerljivo raven kakovosti kot zdravilo Keppra ter da mu je biološko enakovredno.
Levetiracetam Actavis is a ‘generic medicine'. 
Levetiracetam Actavis je „generično zdravilo“.
Levetiracetam Actavis tablets are swallowed with liquid. 
Tablete Levetiracetam Actavis je treba pogoltniti s tekočino.
Levetiracetam Actavis is a medicine that contains the active substance levetiracetam. 
Levetiracetam Actavis je zdravilo, ki vsebuje zdravilno učinkovino levetiracetam.